Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01142947 · ClinicalTrials.gov registry record · NA
Study of Asthma Phenotypes and Pharmacogenomic Interactions by Race-Ethnicity (SAPPHIRE)
A NA study, sponsored by Henry Ford Health System.
- Completed
- Registry status
- NA
- Development phase
- 362
- Enrollment target
NCT01142947 is a NA study that has completed, run by Henry Ford Health System. The registered enrollment target is 362 participants.
The verdict
NCT01142947, a NA study, has completed, sponsored by Henry Ford Health System.
- COMPLETED
- Registry status
- NA
- Development phase
- 362 participants
- Enrollment target
Study Summary
Inhaled corticosteroids (ICS) are considered first-line treatment for persistent asthma, yet little is known about the genetic factors that influence response to this therapy. This study seeks to quantify response to ICS therapy in African American and white patients, as well as look for genetic markers that predict treatment response.
Interventions
- DRUG beclomethasone dipropionate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 362 participants |
| Start Date | 2007-10 |
| Est. Completion | 2019-03-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01142947
The ClinicalTrials.gov registry entry for NCT01142947 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 362 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Henry Ford Health System, which has 234 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which beclomethasone dipropionate is the first listed.
NCT01142947 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01142947 about?
NCT01142947 is a clinical study titled "Study of Asthma Phenotypes and Pharmacogenomic Interactions by Race-Ethnicity (SAPPHIRE)". Inhaled corticosteroids (ICS) are considered first-line treatment for persistent asthma, yet little is known about the genetic factors that influence response to this therapy. This study seeks to quantify response to ICS therapy in African American and white patients, as well as look for genetic mar...
What is the current status of trial NCT01142947?
This trial is currently completed. It is a NA study. The enrollment target is 362 participants. The study started on 2007-10. Estimated completion is 2019-03-11.
What interventions are being tested in trial NCT01142947?
The interventions under investigation include: beclomethasone dipropionate (DRUG).
Who is sponsoring clinical trial NCT01142947?
This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.